H. Lundbeck A/S and Forest Laboratories, Inc. said today that the
U.S. Court of Appeals for the Federal Circuit has affirmed a July 13,
2006 decision by the U.S. District Court for the District of Delaware
which determined that the U.S. patent covering escitalopram, the
active ingredient in Lexapro®, is valid and upheld the injunction
preventing, Ivax/Teva's proposed generic product launch, thereby
confirming Forest's and Lundbeck's patent rights for Lexapro®, which
expire in March 2012.
The patent at issue in the U.S. lawsuit is Lexapro's patent (U.S.
Patent No. Re 34,712), which is set to expire in March 2012 and
covers substantially pure escitalopram.
The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Caroline Broge
Director, Investor Relations Media Relations Manager
+45 36 43 30 79 +45 36 43 26 38
+1 201 350 0187
________________________
Stock Exchange Release No 293 - 5 September 2007
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com
